20 March

Kidney Int http://www.kidney-international.org/

• 00:00
  From bench to bedside: Lessons learned from translational podocyte research - Olivia Lenoir, Tobias B. Huber, Pierre-Louis Tharaux Kidney Int
  Polat et al. report that mice with a podocyte-specific expression of a constitutively-active Rac1 form displayed similar injury and albuminuria, irrespectively of Transient Receptor Potential Canonical 5 (TRPC5) activity. This article confirms the pathogenic role of deregulated Rac1 and (...) (Kidney International (2023))
• 11:46
  Table of Contents Kidney Int
  (Kidney International 103, 4 (2023))
• 11:46
  Subscription Information Kidney Int
  (Kidney International 103, 4 (2023))
• 11:46
  Editorial Board Kidney Int
  (Kidney International 103, 4 (2023))
• 11:46
  Acknowledgment of reviewers Kidney Int
  The Editors are grateful to the following Reviewers who evaluated manuscripts for Kidney International during 2022. (Kidney International 103, 4 (2023))
• 11:46
  journal club Kidney Int
  Takahashi et al., on behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; and Stroke Council. (Circulation. 2022;146:e558–e568.) (Kidney International 103, 4 (2023))
• 11:46
  in this issue Kidney Int
  The Jaffe reaction is the most commonly used test to measure creatinine levels. High levels of glucose can interfere with Jaffe, causing it to overestimate creatinine. Because the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) is increasing dramatically in patients with (...) (Kidney International 103, 4 (2023))
• 11:46
  Glucocorticoids for IgA nephropathy—pro - Yue-Miao Zhang, Ji-Cheng Lv, Muh Geot Wong, Hong Zhang, Vlado Perkovic Kidney Int
  Since IgA nephropathy (IgAN) was first described in 1968 by Jean Berger, supportive lifestyle measures and blood pressure lowering agents, especially renin-angiotensin system inhibitors (RASi), have become first-line treatment. Despite this, a substantial risk of progression remains even when (...) (Kidney International 103, 4 (2023))
• 11:46
  First do no harm: systemic glucocorticoids should not be used for the treatment of progressive IgA nephropathy - Chee Kay Cheung, Jonathan Barratt Kidney Int
  Over recent years, significant progress has been made in the understanding of the pathogenesis of IgA nephropathy (IgAN). A multihit model is widely accepted; in patients with IgAN, there is an increase in circulating poorly galactosylated IgA1, likely to be of mucosal origin, that drives (...) (Kidney International 103, 4 (2023))
• 11:46
  IgA nephropathy and glucocorticoids—a limbo dance? - Brad H. Rovin Kidney Int
  In this issue of Kidney International, arguments are presented for and against the use of systemic glucocorticoids (GCs) in the treatment of IgA nephropathy (IgAN) that is likely to progress. The use of immunomodulation in IgAN makes sense. The immune system, especially the mucosal immune (...) (Kidney International 103, 4 (2023))
• 11:46
  Advances in biodesign: artificial water channels outperforming aquaporins - Ines P.D. Costa, Iain A. Drummond, Olivier Devuyst Kidney Int
  Water channels mediating fast water transport across biological membranes are essential for water balance in all living organisms. The archetypal water channel, aquaporin-1 (AQP1), was cloned from human erythrocytes by Denker et al. in the late 1980s,1 and its function was demonstrated by a (...) (Kidney International 103, 4 (2023))
• 11:46
  Corrigendum to “Myeloid cyclooxygenase-2/prostaglandin E2/E-type prostanoid receptor 4 promotes transcription factor MafB-dependent inflammatory resolution in acute kidney injury.” Kidney Int. 2022;101:79–91 - Yu Pan, Shirong Cao, Andrew S. Terker, Jiaqi Tang, Kensuke Sasaki, Yinqiu Wang, Aolei Niu, Wentian Luo, Dhouha Daassi, Xiaofeng Fan, Suwan Wang, Matthew H. Wilson, Ming-Zhi Zhang, Raymond C. Harris Kidney Int
  The authors of the above-stated article regret the misspelled name of the author Dhouha Daassi. (Kidney International 103, 4 (2023))
• 11:46
  Novel mechanism of increased preeclampsia risk after kidney donation - Elizabeth Ann L. Enninga, Vesna D. Garovic Kidney Int
  Preeclampsia is a hypertensive disorder of pregnancy diagnosed after 20 weeks of gestation in the presence of maternal elevated blood pressures accompanied by proteinuria or organ dysfunction, including kidney insufficiency. Although low-dose aspirin is recommended for preeclampsia prevention (...) (Kidney International 103, 4 (2023))
• 11:46
  Solving the insoluble: calciprotein particles mediate bulk mineral transport - Willi Jahnen-Dechent, Andreas Pasch Kidney Int
  Protein mineral complexes, or calciprotein particles, are formed by calcium, phosphate, and the plasma protein fetuin-A. Crystalline calciprotein particles cause soft tissue calcification, oxidative stress, and inflammation, all well-known complications in chronic kidney disease. The T50 (...) (Kidney International 103, 4 (2023))
• 11:46
  Kidney-specific metabolomic profiling in machine perfusate - Eugene P. Rhee Kidney Int
  Given their accessibility and relevance to established clinical workflows, blood and urine have been the major focus of investigation in metabolomics studies of human kidney disease. In this issue, Liu et al. describe the application of metabolomics to perfusate from donor kidneys subjected to (...) (Kidney International 103, 4 (2023))
• 11:46
  A transitional B-cell cytokine biomarker for risk stratifying renal transplant patients with borderline rejection - Sumoyee Basu, Anthony Dorling, Anita S. Chong Kidney Int
  Borderline allograft rejection can promote acute rejection and graft loss in some, but not all, patients. In this issue, Cherukuri et al. use a novel test based on peripheral blood transitional T1 B cells producing interleukin-10 and tumor necrosis factor-?, which identifies patients at high (...) (Kidney International 103, 4 (2023))
• 11:46
  Fosl1: friend or foe? - Shruti Bhargava, Joachim Jankowski Kidney Int
  Fos-like antigen 1 (Fosl1) is a protein that belongs to the Fos family of transcription factors. Fosl1 has an impact on (i) carcinogenesis, (ii) acute kidney injury, and (iii) fibroblast growth factor expression. Recently, the nephroprotective effect of Fosl1 by the preservation of Klotho (...) (Kidney International 103, 4 (2023))
• 11:46
  Pulmonary-renal syndrome in IgA vasculitis - Sascha T. Bender, Peter R. Mertens, Christian Gross Kidney Int
  A 65-year old man was admitted with acute kidney failure, respiratory difficulty, and hemoptysis. He had a medical history of chronic kidney disease stage 3A. He noted a skin rash starting 4 days before admission, accompanied by arthralgia affecting both knees and ankles, abdominal pain, and (...) (Kidney International 103, 4 (2023))
• 11:46
  Spheroplasts in the urinary sediment - Giovanni Battista Fogazzi, Giuseppe Garigali Kidney Int
  A 33-year-old woman, who 4 months before had received a cadaveric kidney transplant for end-stage kidney disease caused by chronic pyelonephritis, was seen in clinic for routine follow-up. The patient was asymptomatic and was receiving treatment with anti-rejection medications and oral cefixime (...) (Kidney International 103, 4 (2023))
• 11:46
  The Case | Hematuria and hypercalcemia in a kidney transplant recipient - Athiphat Banjongjit, Thunyatorn Wuttiputhanun, Jakapat Vanichanan, Thornthun Ueaphongsukkit, Kroonpong Iampenkhae, Yingyos Avihingsanon, Natavudh Townamchai Kidney Int
  A 25-year-old woman presented with dysuria and intermittent gross hematuria for 2 weeks. She underwent a kidney transplantation 2 years earlier because of end-stage kidney disease of unknown cause. She received basiliximab as induction therapy, followed by maintenance immunosuppression with (...) (Kidney International 103, 4 (2023))